Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tetraphase Raises $45 Mil. In Series C Round, Enough To Finish Phase II For Next-Gen Antibiotic

This article was originally published in The Pink Sheet Daily

Executive Summary

Tetraphase is keeping its exit options open, hoping for either an initial public offering, a licensing deal or an acquisition down the road.

You may also be interested in...



Start-Up Quarterly Statistics, Q2 2010

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.

As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors

VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.

Achaogen Raises $56M In Series C Round To Advance Next-Generation Antibiotic Programs

Achaogen turns to VC backers to advance its lead compound into Phase II trials for complicated urinary tract infections.

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel